Porcine Pert
Exocrine Pancreatic Insufficiency
Entero TherapeuticsPhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Exocrine Pancreatic Insufficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Liprotamase Anthera Pharmaceuticals | Phase 4 | A |
Pancrelipase Anagram Therapeutics, Inc. | Phase 4 | A |
Triheptadecanoin Children's Hospital of Philadelphia | Phase 4 | BB |
Panzytrat Forest Laboratories | Phase 4 | BB |
ADRULIPASE ALFA Entero Therapeutics | Phase 2 | BB |
View all 26 →
Same molecule, other indications
Porcine Pert is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →